Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOGITO: Tadalafil and Cardiac Remodeling in Diabetic Cardiomyopathy
2014-000077-39Phase 3Active
- Sponsor
- Sapienza University of Rome
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of tadalafil in diabetic cardiomyopathy (DCM), type 2 diabetes mellitus (T2DM) and left ventricular hypertrophy (LVH), sponsored by Sapienza University of Rome. Primary endpoint: Left ventricular torsion change by CMR tagging. Started Jan 2014; status: active.
02
Drugs
tadalafil
03
Conditions
diabetic cardiomyopathy (DCM)type 2 diabetes mellitus (T2DM)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on 2014-000077-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000077-39.